Compare GSK plc (GSK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Marsh (MRSH) trades at $181.18, up 1.76% today, near its R3 resistance of $181. The stock shows a bullish technical signal, with recent earnings beats and a 10% dividend increase to $0.99 per share. Revenue grew to $26.98B in 2025, with a net income margin of 14.26%, while the P/E ratio stands at 22.03. Analyst consensus is a buy rating from 11 of 33 analysts, with a price target of $203.67.

The outlook is positive with sustained organic growth and shareholder returns, but risks include rising operating expenses and a premium valuation. Earnings growth and AI initiatives are key catalysts, though softer insurance pricing and debt levels warrant monitoring for potential volatility.